$29.95
1.685.93%
Last update: Nov 6, 2:45 PM
Celldex Therapeutics Inc (CLDX) Stock Price, Quote, News & History
CLDXNASDAQ
Celldex posts positive Phase 3 data for barzolvolimab to treat chronic spontaneous urticaria. The company plans a 2027 FDA submission.
You can purchase shares of Celldex Therapeutics (NASDAQ:CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Celldex Therapeutics has a consensus price target of $60.50.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $29.945 last updated November 6, 2026 at 2:45 PM EST.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune,...
